KEY POINTS
- This retrospective single-center study evaluated 26 consecutive patients with locally advanced periorbital tumors treated using SBRT at Northwell Health between 2021 and 2025. Median age was 75 years, and histologies included 15 cutaneous SCCs, six BCCs, two Merkel cell carcinomas, one sebaceous carcinoma, one solitary fibrous tumor and one metastatic breast carcinoma. Nineteen patients received definitive SBRT and seven underwent postoperative treatment for residual disease.
- Tumors frequently involved anatomically challenging regions, including the canthi in 20/26 patients, orbital septal violation in 18, anterior orbital invasion in 16, and intraconal extension in 15. All patients had preserved ipsilateral vision before treatment, and 13/26 (50%) received systemic therapy at different time points, including immunotherapy, EGFR-targeted therapy or chemotherapy.
- Treatment used photon-based VMAT/IMRT with a simultaneous integrated boost, delivering 35–40 Gy to the gross tumor and 25 Gy to the clinical target volume in five twice-weekly fractions. PTV expansions were generally 2–3 mm, with reductions near critical structures when necessary. For perineural invasion, at-risk nerve pathways were included toward the skull base foramina, while optic nerves, chiasm and globes were contoured with additional 1-mm PRVs.
- Institutional planning objectives included maximum optic nerve and orbital PRV doses ≤30 Gy, mean doses ≤20 Gy, and lacrimal gland mean dose <26 Gy when feasible. Actual maximum ipsilateral optic nerve doses ranged from 0.1 to 26.9 Gy, while optic nerve PRV maxima reached 32.3 Gy. Maximum lens doses reached 33.9 Gy ipsilaterally, emphasizing that meaningful ocular exposure could remain despite highly conformal planning.
- At a median follow-up of 18 months (range 4–50), 21/26 patients (81%) achieved complete response, two had stable disease and three developed locoregional recurrence, including one cavernous sinus failure. Estimated one-year local control was 88% and one-year overall survival was 94%, with no treatment-related deaths. These outcomes were descriptive and were not compared with a matched surgical, conventional RT or proton therapy cohort.
- All 26 patients retained reported functional vision during available follow-up, and no radiation-induced optic neuropathy or permanent blindness was documented. Nevertheless, ocular morbidity occurred, including blurred vision in six patients, epiphora in three, cataract progression in two, and a chronic corneal ulcer requiring surgery in one patient with extensive periorbital involvement. Thus, vision preservation should not be interpreted as absence of clinically meaningful ocular toxicity.
- Acute dermatitis was common, occurring in approximately 92% of patients, predominantly grade 1–2. Grade 3 dermatitis occurred in 2/26 patients (8%), both requiring reconstructive intervention. Long-term interpretation is limited by the small, histologically heterogeneous cohort, nonuniform baseline ophthalmological assessment, concurrent systemic treatments and insufficient follow-up to characterize delayed optic neuropathy, retinopathy or progressive ocular surface damage.
CLINICAL TAKEAWAY
Five-fraction SBRT may provide an eye-preserving alternative for carefully selected patients with locally advanced periorbital tumors when orbital exenteration would cause substantial functional morbidity. The observed local control and short-term vision preservation are encouraging, but severe skin toxicity and late ocular risks remain important, and this small uncontrolled series cannot establish equivalence to surgery, conventional RT or proton therapy.